UPLOAD Filing
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Date: Aug. 7, 2025 · CIK: 0001335105 · Accession: 0000000000-25-008320
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-39717
Letter
Re: LIXTE BIOTECHNOLOGY HOLDINGS, INC. Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 001-39717 Dear Robert Weingarten:
August 7, 2025
Robert Weingarten Vice President and Chief Financial Officer LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard Suite 180 Pasadena, CA 91101
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: David Ficksman, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> August 7, 2025 Robert Weingarten Vice President and Chief Financial Officer LIXTE BIOTECHNOLOGY HOLDINGS, INC. 680 East Colorado Boulevard Suite 180 Pasadena, CA 91101 Re: LIXTE BIOTECHNOLOGY HOLDINGS, INC. Form 10-K for the Fiscal Year Ended December 31, 2024 File No. 001-39717 Dear Robert Weingarten: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David Ficksman, Esq. </TEXT> </DOCUMENT>